Company: RCUS
Filing Date: 2025-10-28
Form Type: 10-Q
Source: 0001724521-25-000116
Chunk: 215

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-28
Form: 10-Q
Item: Part I, Item 1
Chunk 215
---
 securities21.418.7We have also excluded the effect of Gilead’s right to purchase additional shares of our common stock which expired in July 2025, from the calculation as these rights had no intrinsic value at September 30, 2024.

14

Note 8. Stock-based compensation 

Stock-based Compensation ExpenseThe following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Research and development$7 $9 $23 $29 General and administrative7 10 22 30 Total stock-based compensation$14 $19 $45 $59 

Note 9. Cash, cash equivalents and marketable securities 

The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): Types of securities as of September 30, 2025AmortizedCostUnrealizedGainUnrealizedLoss FairValueMoney market funds$171 $— $— $171 U.S. treasury securities246 — — 246 Corporate securities and commercial paper406 — — 406 Certificate of deposit18 — — 18 Total cash, cash equivalents and marketable securities$841 $— $— $841 Types of securities as of December 31, 2024AmortizedCostUnrealizedGainUnrealizedLoss FairValueMoney market funds$120 $— $— $120 U.S. treasury securities251 — — 251 Corporate securities and commercial paper592 — — 592 U.S. government agency securities5 — — 5 Certificate of deposit24 — — 24 Total cash, cash equivalents and marketable securities$992 $— $— $992 The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):Location in Condensed Consolidated Balance SheetsContractual MaturitySeptember 30, 2025December 31, 2024Cash and cash equivalents—$238 $150 Marketable securitiesWithin one year593 828 Long-term marketable